CHAPTER 2
Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress 
A B S T RAC T
Aneuploidy is a hallmark of human solid cancers that arises from errors in mitosis and results in gain and loss of oncogenes and tumour suppressors. Aneuploidy poses a growth disadvantage for cells grown in vitro, suggesting that cancer cells adapt to this burden. To better understand the consequences of aneuploidy in a rapidly proliferating adult tissue we engineered a mouse in which chromosome instability (CIN) was selectively induced in T cells. A flanked-by LOX (FLOX) mutation was introduced into the Mps1 spindle assembly checkpoint (SAC) gene so that Cre-mediated recombination would create a truncated protein (Mps1 DK ) that retained the kinase domain, but lacked the kinetochore-binding domain and thereby weakened the checkpoint. In a sensitized p53 +/-background we observed that Mps1 DK/DK mice suffered from rapid-onset acute lymphoblastic lymphoma (T-ALL). The tumours were highly aneuploid and exhibited a metabolic burden similar to that previously characterized in aneuploid yeast and cultured cells. The tumours nonetheless grew rapidly and were lethal within 3-4 months of birth.
S I G N I F I C A N C E
Normal cells mis-segregate chromosomes only very rarely but the majority of cancer cells have a chromosome instability (CIN) phenotype that makes errors more common and results in abnormal chromosomal content (aneuploidy). Although aneuploidy promotes transformation via gain of oncogenes and loss of tumour suppressors, it also slows cell proliferation and disrupts metabolic homeostasis. Aneuploidy therefore represents a liability as well as a source of selective advantage for cancer cells. In this paper, we provoke CIN in murine T cells by weakening the spindle assembly checkpoint and then study the consequences. We find that CIN dramatically accelerates cancer in a genetically predisposed background and that the resulting aneuploid cancers are metabolically deranged, a vulnerability that may open new avenues to treating aneuploid cancers.
INTRODUCTION
Aneuploidy is a hallmark of oncogenesis, affecting two out of three cancers 1 . Aneuploidy arises during mitosis as a result of chromosome instability (CIN) [2] [3] [4] . The frequent occurrence of CIN in solid human tumours suggests a fundamental link between aneuploidy and cancer 5 . However, primary mouse embryonic fibroblasts (MEFs) carrying a supernumerary chromosome have decreased proliferative potential, as do cells isolated from Down syndrome patients 6, 7 implying that chromosome imbalance imposes a physiological burden that lowers fitness, at least in untransformed cells 6, [8] [9] [10] . In some mouse models, CIN appears to have a significant impact on lifespan at the organismal level, with increased aneuploidy decreasing life expectancy and vice versa [11] [12] [13] . However, it remains poorly understood how the fitness cost imposed by CIN is balanced by its potential to promote oncogenic transformation.
Mouse models of CIN involving conditional or hypomorphic mutations in SAC genes
provide a means to study aneuploidy and assess its impact on cell fitness and oncogenesis.
The SAC detects the presence of maloriented or detached kinetochores during mitosis and arrests cells in metaphase until all pairs of sister chromatids achieve the bioriented geometry that is uniquely compatible with normal disjunction [14] [15] [16] . The SAC constitutes a signaling cascade (comprised of Mps1, Bub, Mad, CenpE and RZZ proteins) that blocks activation of the anaphase promoting complex (APC/C), and thus mitotic progression, until all chromosomes are properly aligned 17 . In the mouse, germline deletion of SAC genes results in early embryonic lethality whereas heterozygous knockout of Mad2 and other SAC genes generates relatively weak tumour phenotypes late in life [2] [3] [4] . Paradoxically, some SAC mutations appear to be both tumour predisposing and tumour suppressing depending on the context (e.g. CenpE heterozygosity) 18 . Hypomorphic BubR1 mutations also have the unexpected property of promoting progeria 11 .
Conditional mutations typically yield tumour phenotypes more representative of human disease than germline mutations 19 , but conditional alleles have been little studied in the case of the spindle checkpoint. We therefore engineered a conditional flanked by Lox (FLOX) mutation into Mps1, a gene thought to function upstream in the SAC pathway 20 and then selectivity truncated the protein by expressing Cre recombinase in T cells. Fig. 1E ). We conclude that the Mps1 DK mutation impairs but does not prevent kinetochore binding, a conclusion supported by over-expression studies in human MCF10A cells (Sup. Fig. 1F , G, Sup. Movies 3, 4).
The Mps1 DK truncation weakens the SAC and causes CIN
To determine the consequences of Mps1 mutation for chromosome segregation at a cellular level, we isolated Mps1 f/f embryos, generated MEFs and transduced them with retroviruses expressing doxycycline-inducible Cre (GFP-T2A-Cre). We found that exposure of these cells to doxycycline (Dox) resulted in highly efficient switching, and then compared the value to aCGH intensity ( Fig 4A-B To begin to identify biological pathways altered by aneuploidy, we compared probes that were up-or downregulated at least 1.5-fold in > 15% of tumours analysed (4 out of 22); ~3300 genes were identified by this analysis. Webgestalt 35 was then used to find GO categories that were significantly enriched (using a Bonferroni corrected p value < 0.05). The most commonly deregulated pathways were T cell receptor signaling, mRNA processing, cell cycle, and pathways involved in cellular metabolism (Sup. Fig.   3E ). When we performed hierarchical clustering of deregulated genes (Fig. 5) , dividing clusters into five groups based on whether genes were strongly or weakly up-or down regulated, T cell differentiation and signaling factors were down-regulated, consistent with histological data showing that tumours are poorly differentiated. In contrast, pathways involved in cellular metabolisms (GO terms for metabolic pathways, RNA metabolic pathways, spliceosome, translation factors, nucleotide synthesis, etc.) were upregulated.
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Misregulation of these processes has previously been associated with aneuploid stress in cultured mammalian cells and budding yeast 6, 8, 36, 37 . We conclude that dysregulation of metabolic pathways is a common feature of CIN in multiple organisms and cell types, including rapidly growing tumours. Taken together these data suggest that Mps1 mutation causes p53 LOH and the combined Mps1-p53 mutant genotype results in more efficient gain and loss of cancer genes than p53 mutation alone.
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We interpret aCGH and interphase FISH data to show that T-ALLs are initially clonal wrote the paper.
MATERIALS & METHODS

Analysis of mice
Mice used in this study had a mixed C57BL/6 and 129/Sv D3 genetic background. Mps1 conditional mice harbouring a deletion of residues 47 to 154 were generated as described in supplemental methods. p53 conditional knockout mice were obtained from Anton
Berns (25), Lck-Cre transgenic mice from Taconic 38 , and MMTV-Cre mice 39 from the MIT mouse repository. Mice were intercrossed to obtain the described strains and genotyped as described previously 25, 39 (genotyping PCR primers in Sup. info S5). For survival studies, mice were monitored for tumour development weekly starting at 2.5 months of age by looking for difficulty in breathing (a consequence of thymic hypertrophy). Tissues were fixed in 10% formalin and then paraffin-embedded for histology. Animal protocols were approved by the MIT, HMS and UMCG Committees on Animal Care and the UK Home
Office.
MEF isolation, transduction, flow cytometry and time-lapse analysis.
MEFs were isolated as described before 40 
DNA/RNA/protein isolation, array and blotting experiments
Genomic DNA from tumour samples and control liver was isolated using genomic DNA tissue kits (Qiagen). Genotyping primers can be found in Sup. info S5. Protein was isolated using a total protein extraction kit (Millipore). For protein detection, proteins were blotted using standard Western blotting protocols. Used antibodies were TTK (Santa Cruz, C19) and HRP-conjugated goat ant rabbit (Cell Signaling). For aCGH experiments, labelled DNA (see Sup. Methods) was hybridized to 244K mouse genome CGH arrays (Agilent) according to manufacturer's protocol and analysed as described in supplemental methods. RNA was isolated from tumour samples and thymuses from 6 weeks old control mice using the RNeasy kit (Qiagen). Labelled RNA (see Sup. methods) was hybridized to Illumina v6.2 beadchip arrays, scanned and analysed as described in the supplemental methods. qPCR primers can be found in Sup. info S5. All array data has been deposited at NCBI GEO under accession number GSE57334.
SUPPLEMENTAL MATERIALS & METHODS
Generation of Mps1 f conditional and Mps1
D mutant mice A 129/Sv mouse genomic lambda-phage library was screened for the genomic locus of by digesting a lambda phage clone with SacI and XmaI which contained sequences 5' of the targeting vector and then subcloned into pBluescript (Invitrogen). The 5' probe yields an 11.7 kb wild type band and a 9 kb targeted band. The 3' probe is homologous to sequences containing exon 9 of Mps1 and was generated by PCR yielding a 13.4 kb wild type band and a 9.4 kb targeted band. Two correctly targeted ES clones were isolated.
The LFNT cassette was removed in these ES clones by transfecting cells with vectors expressing Cre recombinase (pCrePac) or Flp recombinase (pFlpe), which resulted in the DK (Sup. Fig 1A line 5) or conditional (f) (Sup. Fig. 1A line 4) allele, respectively.
Southern blotting after restriction digestion with NcoI and probing with the 5' 664 bp probe yielded 8 kb for wild type, 12 kb for the targeted locus (containing LFNT), 15.2 kb for the DK allele and 18.6 kb for the f-allele. Three DK/+ and two f/+ subclones from the two original clones were injected into blastocyts and successfully generated founder lines for the conventional DK and conditional alleles.
To assess the consequences of Mps1 truncation in developing embryos, we generated mice comprised 38% of viable pups and Mps1 DK/+ 62% of pups, the expected Mendelian ratio; Sup. Fig. 5B ). Timed matings (E10.5 embryos were isolated and the yolk sac taken to determine genotype by PCR as described 2 revealed that Mps1 DK/DK embryos died at or before E10 (Sup. Fig. 5C ), as previously described for germline deletion of other checkpoint genes [3] [4] [5] . We conclude that aneuploidy generated by the Mps1 DK allele is lethal to developing embryos.
Generation of pRetrox GFP-Mps1 full length, pRetrox GFP-Mps1DK and Cre-T2A-GFP.
For pRetrox GFP-Mps1 vectors, we first PCR amplified eGFP (Phusion polymerase, Thermo Scientific) with BglII and BamHI+NotI Sites 5' and 3' respectively. This PCR fragment was cloned into BamH1, NotI-digested (New England Biolabs) a pRetrox backbone (Clontech) thus destroying the BamH1 site 5' of the GFP. In case of full length Mps1, we then PCR-amplified Mps1 from a human Mps1 cDNA clone (Harvard clone library) flanked by BamH1 and NotI sites 5' and 3' respectively, which was cloned into pRetrox-eGFP digested with BamH1 and NotI. For Mps1 DK , we first PCR-amplified a fragment encompassing the 5' ATG to an endogenous HindII site in exon 1 of human Mps1, which was ligated into a pMSCV backbone (Clontech) digested with BamH1 and HindIII. We next PCR-amplified Mps1 from the start of exon 4 fused to remained sequence of exon 1 downstream of the endogenous HindIII site to its stop codon, which was ligated into pMSCV containing exon 1 of Mps1 from the previous step, thus Screating Mps1 DK .
We then PCR-amplified Mps1 DK from pMSCV Mps1 DK using BglII and NotI sites and cloned it into pRetrox eGFP similar to full length Mps1. For Cre-T2A-GFP, we first PCR amplified GFP while adding a T2A sequence to its 3' end 6 flanked by BglII and BamH1-NotI sites, which was cloned into pRetrox using BamH1 and NotI sites. We next cloned
Cre downstream of GFP-T2A using BamH1 and NotI sites 5' and 3' respectively. All used primers can be found in Sup. info S5.
Quantification of kinetochore-bound Mps1
To quantify the levels of GFP-Mps1 bound to kinetochores, fluorescence arbitrary units on a horizontal line through a kinetochore were analysed in SoftWorx software (GE Healthcare) using the line-profiling tool. To correct for GFP-tagged protein expression levels, we normalized kinetochore-bound values by subtracting the average GFP expression counts in the cell from the counts at the kinetochore (line-profiling tool). We then calculated the fluorescence ratios between GFP-Mps1 and GFP-Mps1 DK for both cell types, as presented in Sup. Figs. 1E and G.
Comparative Genome Hybridization and analysis
For aCGH experiments DNA was labelled with Cy3 or Cy5 fluorescent nucleotides according to the BioPrime array CGH genomic labelling protocol (Life) and cleaned using purelink PCR purification kit (Life). Many liver samples showed evidence of T cell infiltration, disqualifying them as control samples. Therefore we used pooled sexmatched reference samples from un-infiltrated livers from littermates. Labelled DNA was hybridized to 244K mouse genome CGH microarrays (Agilent) according to the manufacturer's protocol, which were subsequently scanned, background corrected and normalized using the loess algorithm with Bioconductor limma package 7 . Data was then segmented and split into regions of estimated equal copy number using a CBS (Circular Binary Segmentation) algorithm (Bioconductor) with the DNAcopy package 8 .
To further reduce noise, we used the "undo" method to remove all splits that are not at least 3 standard deviations apart. Log2 ratios (tumour/reference) were plotted along the chromosome coordinates using the same software. To create a multi-sample matrix, .
RT-PCR, qPCR, and expression arrays
Synthesis of biotin-labelled cRNA was performed using a Illumina totalprep RNA amplification kit (Ambion). 1.5µg of amplified biotinylated cRNA was hybridized to llumina Sentrix BeadChips (v6.2) and subsequently labelled with streptavidin-conjugated 
